designer491/iStock via Getty Images The U.S. FDA has granted marketing authorization to the Xpert HCV test and GeneXpert Xpress System, the first-ever point-of-care test for hepatitis C, from Danaher (NYSE:DHR) subsidiary Cepheid. The test can be performed in places such as doctors’ offices, emergency departments, and urgent care clinics. TheContinue Reading
Rite Aid (OTC:RADCQ) is seeking approval from a bankruptcy court for its restructuring plan that will cut $2B in debt and emerge from Chapter 11 owned by a group of investors. The company argues that the restructuring plan is the best option to pay its creditors and resume operations, ReutersContinue Reading
U.Today – Take a look at the top three news stories brought to you by U.Today. If (BTC) drops below $57,000, these 3 things will happen Since instead of conquering new highs, Bitcoin has been recently dropping to new lows, one should be ready for various scenarios in order toContinue Reading
tylim Health Canada has authorized Eli Lilly’s atopic dermatitis treatment Ebglyss (lebrikizumab). The biologic is a first-line therapy for those 12 years and older. Ebglyss is given every four weeks, and trials showed that skin clearance and itch relief was seen as soon as four weeks. Ebglyss was approved inContinue Reading
Solitario Resources (NYSE:XPL) (TSX:SLR:CA) on Monday announced that its final revised plan of operations for its Golden Crest project has been signed by US Forest Service. The company added that the South Dakota board of minerals has accepted Solitario’s reclamation bond, paving the way for exploration drilling to begin. TheContinue Reading
Waldemarus/iStock via Getty Images Argenx (NASDAQ:ARGX) has received FDA approval for Vyvgart Hytrulo for the treatment of adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The Dutch biotech company said the product was the first and only neonatal Fc receptor blocker approved to treat the condition. Vyvgart Hytrulo is alsoContinue Reading
jetcityimage/iStock Editorial via Getty Images Takeda (NYSE:TAK) has received EU regulatory approval for Fruzaqla for the treatment of patients with metastatic colorectal cancer who have been previously treatmed with standard therapies and who have progressed while on or are intolerant of treatment with trifluridine-tipiracil or regorafenib. The approval follows aContinue Reading
JasonDoiy The U.S. has granted approval to Roche (OTCQX:RHHBY)-owned Genentech’s biologic crovalimab to treat the rare condition paroxysmal nocturnal hemoglobinuria. The application was supported by two phase 3 trials, one of which demonstrated that crovalimab achieved disease control and was well-tolerated while the other showed a consistent benefit-risk for theContinue Reading
